» Articles » PMID: 11788719

Allosteric Inhibitors of Telomerase: Oligonucleotide N3'-->P5' Phosphoramidates

Overview
Specialty Biochemistry
Date 2002 Jan 15
PMID 11788719
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Telomerase is a ribonucleoprotein responsible for maintaining telomeres in nearly all eukaryotic cells. The enzyme is able to utilize a short segment of its RNA subunit as the template for the reverse transcription of d(TTAGGG) repeats onto the ends of human chromosomes. Transfection with telomerase was shown to confer immortality on several types of human cells. Moreover, telomerase activation appears to be one of the key events required for malignant transformation of normal cells. Inhibition of telomerase activity in transformed cells results in the cessation of cell proliferation in cultures and provides the rationale for the selection of telomerase as a target for anticancer therapy. Using oligonucleotide N3'-->P5' phosphoramidates (NPs) we have identified a region of the human telomerase RNA subunit (hTR) approximately 100 nt downstream from the template region whose structural integrity appears crucial for telomerase enzymatic activity. The oligonucleotides targeted to this segment of hTR are potent and specific inhibitors of telomerase activity in biochemical assays. Mutant telomerase, in which 3 nt of hTR were not complementary to a 15 nt NP, was found to be refractory to inhibition by that oligonucleotide. We also demonstrated that the binding of NP, oligonucleotides to this hTR allosteric site results in a marked decrease in the affinity of a telomerase substrate (single-stranded DNA primer) for the enzyme.

Citing Articles

Anticancer Properties of Novel Bis-Triazoles.

Saleh M, Abuarqoub D, Hammad A, Hossan M, Ahmed N, Aslam N Curr Issues Mol Biol. 2023; 45(1):175-196.

PMID: 36661500 PMC: 9858002. DOI: 10.3390/cimb45010014.


P-stereocontrolled synthesis of oligo(nucleoside N3'→O5' phosphoramidothioate)s - opportunities and limitations.

Radzikowska E, Kaczmarek R, Korczynski D, Krakowiak A, Mikolajczyk B, Baraniak J RSC Adv. 2022; 10(58):35185-35197.

PMID: 35515667 PMC: 9056831. DOI: 10.1039/d0ra04987e.


Mapping targetable sites on human telomerase RNA pseudoknot/template domain using 2'-OMe RNA-interacting polynucleotide (RIPtide) microarrays.

Gude L, Berkovitch S, Santos W, Kutchukian P, Pawloski A, Kuimelis R J Biol Chem. 2012; 287(22):18843-53.

PMID: 22451672 PMC: 3365779. DOI: 10.1074/jbc.M111.316596.


Pancreatic cancer stem cells: fact or fiction?.

Bhagwandin V, Shay J Biochim Biophys Acta. 2009; 1792(4):248-59.

PMID: 19233264 PMC: 2670354. DOI: 10.1016/j.bbadis.2009.02.007.


Targeting human telomerase for cancer therapeutics.

Guittat L, Alberti P, Gomez D, De Cian A, Pennarun G, Lemarteleur T Cytotechnology. 2008; 45(1-2):75-90.

PMID: 19003245 PMC: 3449961. DOI: 10.1007/s10616-004-5127-z.


References
1.
Dragon F, Pogacic V, Filipowicz W . In vitro assembly of human H/ACA small nucleolar RNPs reveals unique features of U17 and telomerase RNAs. Mol Cell Biol. 2000; 20(9):3037-48. PMC: 85579. DOI: 10.1128/MCB.20.9.3037-3048.2000. View

2.
Yang J, Chang E, Cherry A, Bangs C, Oei Y, Bodnar A . Human endothelial cell life extension by telomerase expression. J Biol Chem. 1999; 274(37):26141-8. DOI: 10.1074/jbc.274.37.26141. View

3.
Girardi A, JENSEN F, KOPROWSKI H . SV40-INDUCED TRANFORMATION OF HUMAN DIPLOID CELLS: CRISIS AND RECOVERY. J Cell Comp Physiol. 1965; 65:69-83. DOI: 10.1002/jcp.1030650110. View

4.
Gluzman Y . SV40-transformed simian cells support the replication of early SV40 mutants. Cell. 1981; 23(1):175-82. DOI: 10.1016/0092-8674(81)90282-8. View

5.
Gryaznov S . Oligonucleotide N3'-->P5' phosphoramidates as potential therapeutic agents. Biochim Biophys Acta. 2000; 1489(1):131-40. DOI: 10.1016/s0167-4781(99)00151-7. View